GlassScriptPhysician profile
Daniel J Pak
NPI 1558705301
$117,045.71
in general payments reported to CMS, 2019-2025
22 companies · $33K in 2025
The $33K reported for 2025 was more than what 98% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,284 · 2020: $1,470 · 2021: $1,917 · 2022: $35K · 2023: $18K · 2024: $25K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Consulting Fee: $15K · Honoraria: $13K · Travel and Lodging: $12K · Food and Beverage: $9,691 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,800.00 |
| Consulting Fee | $15,236.25 |
| Honoraria | $13,250.00 |
| Travel and Lodging | $12,489.86 |
| Food and Beverage | $9,690.95 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,016.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $28,177.48 | 2019-2024 | Senza |
| Grt US Holding, INC. | $24,824.78 | 2022 | |
| Globus Medical, INC. | $17,047.27 | 2025 | Senza, Vyrsa V1 |
| Averitas Pharma INC. | $16,611.21 | 2023-2025 | Qutenza |
| Mml US, INC. | $14,036.10 | 2021-2025 | Reactiv8 |
| Medtronic, INC. | $5,259.02 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Relievant Medsystems, INC. | $2,759.57 | 2021-2023 | Intracept |
| Vertos Medical, INC. | $2,276.07 | 2019-2023 | Mild Device Kit |
| Boston Scientific Corporation | $1,199.77 | 2022-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Medtronic USA, INC. | $1,181.39 | 2019 | |
| Abbott Laboratories | $1,028.80 | 2019-2025 | Proclaim, Eterna |
| Stratus Medical, LLC | $930.26 | 2020-2025 | Nimbus |
| Spr Therapeutics, INC | $568.09 | 2023-2025 | Sprint Pns System |
| Biotronik Nro, INC. | $219.12 | 2025 | Prospera |
| Saluda Medical Americas, INC. | $216.73 | 2023 | Evoke Scs |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $159.26 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.00 | 2024 | Relistor |
| Nalu Medical, INC. | $140.02 | 2021 | |
| Gilead Sciences, INC. | $117.81 | 2024 | Epclusa |
| Siemens Medical Solutions USA, INC. | $92.95 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $42.19 | 2025 | |
| Allergan, INC. | $14.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Pak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.